Healthcare and Biotech Stocks Surge in After-Hours Trading: Sensei, Praxis, Cooper, Vanda, Cue, ResMed
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 05 2025
0mins
Should l Buy RMD?
Source: NASDAQ.COM
Sensei Biotherapeutics Surge: Sensei Biotherapeutics Inc. saw a significant after-hours increase of 62.9% to $17.20, following a previous rise and a report of a narrower third-quarter net loss compared to the previous year.
Praxis Precision Medicines Progress: Praxis Precision Medicines, Inc. rose 24.8% to $237.10 after positive EMBOLD study results led to an early recommendation for stopping the study, with plans for an NDA filing in early 2026.
CooperCompanies Financial Update: The CooperCompanies, Inc. climbed 13.0% to $87.01 after reporting a fourth-quarter net income decline but positive revenue growth, alongside a strategic review to enhance shareholder value.
Vanda Pharmaceuticals FDA Approval: Vanda Pharmaceuticals Inc. gained 7.5% to $5.59 after the FDA lifted a partial clinical hold on a protocol, allowing for expanded dosing of tradipitant following a successful dispute resolution request.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RMD
Wall Street analysts forecast RMD stock price to rise
11 Analyst Rating
6 Buy
5 Hold
0 Sell
Moderate Buy
Current: 256.260
Low
260.00
Averages
294.00
High
345.00
Current: 256.260
Low
260.00
Averages
294.00
High
345.00
About RMD
ResMed Inc. is a holding company. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. It also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
RESMED INC - FACILITY EXPECTED TO HIRE MORE THAN 100 EMPLOYEES
- Facility Employment: A new facility is projected to employ over 100 workers.
- Economic Impact: The establishment of this facility is expected to positively influence the local economy.
See More
RESMED INC TO LAUNCH NEW CENTER IN 2027, ENHANCING U.S. PRESENCE
Operational Launch: ResMed is set to begin operations in 2027, marking a significant milestone for the company.
Expansion Plans: The initiative aims to enhance ResMed's presence in the U.S. market, indicating a strategic move for growth.
See More
RESMED GROWS U.S. PRESENCE WITH NEW DISTRIBUTION CENTER IN GREENWOOD, INDIANA
Expansion of U.S. Operations: RESMED has expanded its operations in the U.S. with a new distribution center located in Greenwood, Indiana.
Strategic Location: The new facility is strategically positioned to enhance the efficiency of RESMED's distribution network across the United States.
See More
ResMed Price Target Raised to $302 by KeyBanc Following Strong Earnings
- Analyst Confidence Boost: KeyBanc Capital Markets raised ResMed's price target from $299 to $302 while maintaining an Overweight rating, reflecting increased confidence in the company's future performance.
- Earnings Beat Expectations: ResMed's Q2 fiscal 2026 revenue exceeded expectations, driven primarily by strong performance in the Masks & Accessories and Devices segments, offsetting underwhelming results from the Software as a Service (SaaS) segment.
- Gross Margin Guidance Raised: The company raised the low end of its gross margin guidance for fiscal 2026, indicating improving profitability expectations, with a current gross margin of 60.69%, which further boosts investor confidence.
- Strong Market Performance: RBC Capital Markets increased ResMed's price target from $311 to $314, highlighting double-digit revenue and earnings growth across markets, while maintaining an Outperform rating, indicating a positive outlook for shareholder returns.
See More
XOVR Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: XOVR's 52-week low is $13.9246 per share, with a high of $21.78, while the latest trade price stands at $17.39, indicating price volatility within this range that may influence investor buying decisions.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable technical insights for investors, helping to assess price trends and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade similarly to stocks, where investors are actually buying and selling 'units' that can be created or destroyed based on demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in outstanding shares for ETFs focuses on those experiencing notable inflows (new units created) or outflows (old units destroyed), assessing their impact on the underlying assets.
See More
ResMed Q2 Earnings Beat Expectations with Strong Sales Growth
- Earnings Beat: ResMed reported adjusted earnings of $2.81 for Q2 FY2026, exceeding the consensus estimate of $2.72, indicating a robust performance in profitability.
- Significant Sales Growth: Quarterly sales rose 11% year-over-year to $1.42 billion, surpassing the consensus of $1.396 billion, reflecting strong demand for sleep devices and accessories.
- Smart Comfort Device Approval: The FDA cleared ResMed's Personalized Therapy Comfort Settings (PTCS) for marketing as Smart Comfort, set to launch in early 2026, showcasing the company's innovation in obstructive sleep apnea treatment.
- Margin Improvement: Gross margin increased by 320 basis points to 61.8%, driven by manufacturing and logistics efficiencies, highlighting successful cost management strategies.
See More
RESMED INC - FACILITY EXPECTED TO HIRE MORE THAN 100 EMPLOYEES
- Facility Employment: A new facility is projected to employ over 100 workers.
- Economic Impact: The establishment of this facility is expected to positively influence the local economy.
See More
RESMED INC TO LAUNCH NEW CENTER IN 2027, ENHANCING U.S. PRESENCE
Operational Launch: ResMed is set to begin operations in 2027, marking a significant milestone for the company.
Expansion Plans: The initiative aims to enhance ResMed's presence in the U.S. market, indicating a strategic move for growth.
See More
RESMED GROWS U.S. PRESENCE WITH NEW DISTRIBUTION CENTER IN GREENWOOD, INDIANA
Expansion of U.S. Operations: RESMED has expanded its operations in the U.S. with a new distribution center located in Greenwood, Indiana.
Strategic Location: The new facility is strategically positioned to enhance the efficiency of RESMED's distribution network across the United States.
See More
ResMed Price Target Raised to $302 by KeyBanc Following Strong Earnings
- Analyst Confidence Boost: KeyBanc Capital Markets raised ResMed's price target from $299 to $302 while maintaining an Overweight rating, reflecting increased confidence in the company's future performance.
- Earnings Beat Expectations: ResMed's Q2 fiscal 2026 revenue exceeded expectations, driven primarily by strong performance in the Masks & Accessories and Devices segments, offsetting underwhelming results from the Software as a Service (SaaS) segment.
- Gross Margin Guidance Raised: The company raised the low end of its gross margin guidance for fiscal 2026, indicating improving profitability expectations, with a current gross margin of 60.69%, which further boosts investor confidence.
- Strong Market Performance: RBC Capital Markets increased ResMed's price target from $311 to $314, highlighting double-digit revenue and earnings growth across markets, while maintaining an Outperform rating, indicating a positive outlook for shareholder returns.
See More
XOVR Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: XOVR's 52-week low is $13.9246 per share, with a high of $21.78, while the latest trade price stands at $17.39, indicating price volatility within this range that may influence investor buying decisions.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable technical insights for investors, helping to assess price trends and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade similarly to stocks, where investors are actually buying and selling 'units' that can be created or destroyed based on demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in outstanding shares for ETFs focuses on those experiencing notable inflows (new units created) or outflows (old units destroyed), assessing their impact on the underlying assets.
See More
ResMed Q2 Earnings Beat Expectations with Strong Sales Growth
- Earnings Beat: ResMed reported adjusted earnings of $2.81 for Q2 FY2026, exceeding the consensus estimate of $2.72, indicating a robust performance in profitability.
- Significant Sales Growth: Quarterly sales rose 11% year-over-year to $1.42 billion, surpassing the consensus of $1.396 billion, reflecting strong demand for sleep devices and accessories.
- Smart Comfort Device Approval: The FDA cleared ResMed's Personalized Therapy Comfort Settings (PTCS) for marketing as Smart Comfort, set to launch in early 2026, showcasing the company's innovation in obstructive sleep apnea treatment.
- Margin Improvement: Gross margin increased by 320 basis points to 61.8%, driven by manufacturing and logistics efficiencies, highlighting successful cost management strategies.
See More
